No abstract

No abstract

The tolerance and antitumor activity of Lonidamine combined with radiotherapy were studied on 40 patients with head and neck cancer and compared with a historical control group. Lonidamine was well tolerated. 26 and 17 complete responses were seen in the Lonidamine-treated group and in the historical control group, respectively.

No abstract

Up-to-date unsatisfactory results obtained in multimodality treatments of malignant glioma have prompted the research of new therapeutic modalities with 'unconventional' modes of action. Lonidamine (LND) is a drug which reduces aerobic glycolytic activity in both human and experimental tumors. This effect mainly depends on the inhibition of mitochondrially-bound hexokinase (HK) which is present in large amounts in malignant cells. A Phase II study was conducted on patients with recurrent glioma; 12 patients were admitted to the study. Clinical side effects were moderate, necessitating a reduction of the dosage in only 1 case. The objective results were evaluated according to the indications of Levin. 2 responders and 3 cases of stable disease were observed out of 10 evaluable patients. The potential value of this new drug is discussed.